+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prognostic factors with a multivariate analysis for survival pfas in advanced non small cell lung cancer overview of experience of the european lung cancer working party



Prognostic factors with a multivariate analysis for survival pfas in advanced non small cell lung cancer overview of experience of the european lung cancer working party



Proceedings of the American Association for Cancer Research Annual Meeting 32: 190




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 032977416

Download citation: RISBibTeXText


Related references

Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. Journal of Clinical Oncology 13(5): 1221-1230, 1995

Survival and long term survival analysis in advanced non small cell lung cancer (Nsclc): The experience of the European lung cancer working party. Lung Cancer 8(5-6): 354, 1993

Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 Years experience of the European Lung Cancer Working Party. European Journal of Cancer 33(14): 2326-2332, 1997

Response to chemotherapy has a discriminant value on the distribution of further survival for patients with advanced non small cell lung cancer A ten-year experience of the European Lung Cancer Working Party. European Respiratory Journal Suppl. 10(25): 426S, 1997

Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Journal of Thoracic Oncology 3(1): 6, 2008

Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. Journal of Thoracic Oncology 5(5): 612-619, 2010

Prognostic factors in advanced stage non-small cell bronchial cancer: experiences of the European Lung Cancer Working Party. Revue des Maladies Respiratoires 14(6): 445-449, 1997

Primary tumour standardized uptake value (SUV max) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Staging Project. 2007

Poster Primary tumour standardized uptake value (Suv max) measured on fluorodeoxyglucose positron emission tomography (Fdg-Pet) is of prognostic value for survival in non-small cell lung cancer (Nsclc): a systematic review and meta-analysis (Ma) by the European Lung Cancer Working Party for the Iaslc Staging Project. European Journal of Cancer Suppl.s 5(4): 364-365, 2007

A randomized trial of two platinum combinations in patients with advanced non-small cell lung cancer: a preliminary report. European Organization for the Research and Treatment of Cancer--Lung Cancer Working Party. Seminars in Oncology 17(1 Suppl 2): 20-24, 1990

Treatment of non-small cell lung cancer: advanced (metastatic) disease. Guidelines of clinical practice made by the European Lung Cancer Working Party. Revue Medicale de Bruxelles 28(6): 495-511, 2008

Induction chemotherapy with ifosfamide, etoposide, and anthracycline for small cell lung cancer: experience of the European Lung Cancer Working Party. Seminars in Oncology 22(1 Suppl 2): 18-22, 1995

Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party. Journal of Clinical Oncology 16(4): 1388-1396, 1998

A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party. British Journal of Cancer 68(6): 1150-1156, 1993

Chemotherapy in non small cell lung cancer an overview of 12 years experience in a european cooperative study group eortc lung cancer study party. Bulletin du Cancer 77(10): 997-1005, 1990